Acceleron report positive phase I results for myostatin inhibitor

Published Date
19/07/2016
Author
Jenny Sharpe
Category
Research
Orange box stating: Breaking news research

The pharmaceutical company, Acceleron, recently announced the results of its phase I clinical trial testing ACE-083 in healthy people. ACE-083 is an investigational protein therapeutic that binds and blocks the action of a family of proteins that negatively regulate muscle growth (including the myostatin protein).

The trial results showed that ACE-083 was safe and significantly increased the volume of the muscle that it was injected into. According to their press release, Acceleron intends to advance ACE-083 into a phase II clinical trial for people with facioscapulohumeral muscular dystrophy (FSHD).

Keep in touch